Evidence map›Paper›PMID 37466802›Full record

ArticleNeurochemical research2023

Long-term Effects of the pituitary-adenylate cyclase-activating Polypeptide (PACAP38) in the Adult Mouse Retina: Microglial Activation and Induction of Neural Proliferation.

Viktoria Denes, Akos Lukats, Gergely Szarka, Rovena Subicz, Adrienn Mester, Andrea Kovacs-Valasek, Peter Geck, Gergely Berta, Robert Herczeg, Etelka Postyeni and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurochemical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Non-neuronal targets for migraine therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  2. Microglial polarization in retinal neovascularization: Friend or foe?Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Viktoria DenesDepartment of Neurobiology, University of Pécs, 6 Ifjúság str, Pécs, H-7624, Hungary. vdenes@gamma.ttk.pte.hu.
Akos LukatsInstitute of Translational Medicine, Translational Retina Research Group, Semmelweis University, Budapest, Hungary.
Gergely SzarkaDepartment of Neurobiology, University of Pécs, 6 Ifjúság str, Pécs, H-7624, Hungary.
Rovena SubiczDepartment of Neurobiology, University of Pécs, 6 Ifjúság str, Pécs, H-7624, Hungary.
Adrienn MesterDepartment of Neurobiology, University of Pécs, 6 Ifjúság str, Pécs, H-7624, Hungary.
Andrea Kovacs-ValasekDepartment of Neurobiology, University of Pécs, 6 Ifjúság str, Pécs, H-7624, Hungary.
Peter GeckDepartment of Medical Education, School of Medicine, Tufts University, 136 Harrison Ave, Boston, MA, 02111, USA.
Gergely BertaDepartment of Medical Biology and Central Electron Microscope Laboratory, Medical School, University of Pécs, Pécs, Hungary.
Robert HerczegJános Szentágothai Research Centre, Bioinformatics Research Group, University of Pécs, 20 Ifjúság str, Pécs, H-7624, Hungary.
Etelka PostyeniDepartment of Neurobiology, University of Pécs, 6 Ifjúság str, Pécs, H-7624, Hungary.
Attila GyeneseiJános Szentágothai Research Centre, Bioinformatics Research Group, University of Pécs, 20 Ifjúság str, Pécs, H-7624, Hungary.
Robert GabrielDepartment of Neurobiology, University of Pécs, 6 Ifjúság str, Pécs, H-7624, Hungary.
University of Pecs · HUSemmelweis University · HUTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The degenerative retinal disorders characterized by progressive cell death and exacerbating inflammation lead ultimately to blindness. The ubiquitous neuropeptide, PACAP38 is a promising therapeutic agent as its proliferative potential and suppressive effect on microglia might enable cell replacement and attenuate inflammation, respectively. Our previous finding that PACAP38 caused a marked increase of the amacrine cells in the adult (1-year-old) mouse retina, served as a rationale of the current study. We aimed to determine the proliferating elements and the inflammatory status of the PACAP38-treated retina. Three months old mice were intravitreally injected with 100 pmol PACAP38 at 3 months intervals (3X). Retinas of 1-year-old animals were dissected and effects on cell proliferation, and expression of inflammatory regulators were analyzed. Interestingly, both mitogenic and anti-mitogenic actions were detected after PACAP38-treatment. Further analysis of the mitogenic effect revealed that proliferating cells include microglia, endothelial cells, and neurons of the ganglion cell layer but not amacrine cells. Furthermore, PACAP38 stimulated retinal microglia to polarize dominantly into M2-phenotype but also might cause subsequent angiogenesis. According to our results, PACAP38 might dampen pro-inflammatory responses and help tissue repair by reprogramming microglia into an M2 phenotype, nonetheless, with angiogenesis as a warning side effect.

Indexed as

MicrogliaPituitary Adenylate Cyclase-Activating PolypeptideAdenylyl CyclasesAnimalsEndothelial CellsMiceRetinaAdenylyl CyclasesPituitary Adenylate Cyclase-Activating PolypeptideAdult retinaAngiogenesisInflammationMicrogliaPACAP38Proliferation

Identifiers

PMID37466802
PMCPMC10514177
OpenAlexW4384663357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.